VERTEX PHARMACEUTICALS INC (VRTX)
US92532F1003 - Common Stock
VERTEX PHARMACEUTICALS INC
NASDAQ:VRTX (4/15/2024, 7:00:02 PM)
After market: 397.65 +0.29 (+0.07%)397.36
+0.81 (+0.2%)
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 4,800 full-time employees. The firm is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The firm has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
Company Info
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS 02210
P: 16173416393
CEO: Reshma Kewalramani
Employees: 4800
Website: https://www.vrtx.com/
VRTX News
12 hours ago - The Motley FoolHere's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals StockVertex just laid claim to an asset that might be very valuable.
Vertex just laid claim to an asset that might be very valuable.
3 days ago - The Motley FoolCould This Stock Be the Next Biotech Buyout?Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.
3 days ago - Investor's Business DailyStock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly ReviewThe stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears.
4 days ago - InvestorPlaceWall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024.
4 days ago - InvestorPlaceRaymond James Just Raised Its Price Target on Nvidia (NVDA) StockNvidia stock is on the move Thursday after shares of NVDA got an increased price target of $1,100 from Raymond James analysts.
VRTX Twits
Here you can normally see the latest stock twits on VRTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
